# Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

> **NCT07373990** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 418 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)
- Nasopharyngeal Cancer

## Interventions

- **DRUG:** tislelizumab
- **DRUG:** tislelizumab
- **DRUG:** Gemcitabine + cisplatin (GP)
- **DRUG:** Cisplatin (100mg/m2)
- **RADIATION:** intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT07373990
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2028-04-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 418 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07373990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07373990, "Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07373990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*